dr. ellis on adjuvant cdk4/6 inhibition in hr-positive breast cancer
Published 5 years ago • 95 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:05
dr. ellis on potential impact of cdk4/6 inhibitors in breast cancer
-
1:39
dr. ellis on abemaciclib in hr-positive breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
0:22
copy of dr. ellis on abemaciclib in hr-positive breast cancer
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
1:25
dr. ellis on neoadjuvant endocrine therapy for breast cancer
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
2:58
patients’ perspectives on cdk4/6 inhibitors
-
0:50
dr. ellis on immunotherapy in her2 breast cancer
-
1:58
dr. yardley on endocrine therapy plus cdk4/6 inhibitors in breast cancer with visceral metastases
-
8:28
cdk4/6 inhibition in breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy